SCHEMBL2625327

SCHEMBL2625327

CCCN1CC(=O)c2c(C)nc(-c3ccc(C)cc3)nc2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.36
SIGMAR1 Q99720 2/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
CHRM3 P20309 1/20 0.34
TMEM97 Q5BJF2 1/20 0.34
ADORA3 P0DMS8 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2D6 P10635 1/20 0.33
NPC1 O15118 3/20 0.33
LMNA P02545 3/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2625328 0.82 KCNH2 (0.39) KCNH2SIGMAR1CHRM2CHRM4CHRM5
SCHEMBL2625326 0.76 TLR9 (0.39) KCNH2SIGMAR1CHRM2CHRM4CHRM5
SCHEMBL10220350 0.74 HTR1A (0.39) KCNH2ADORA3L3MBTL1ALDH1A1NPC1
SCHEMBL2625321 0.73 DRD2 (0.43) KCNH2SIGMAR1CHRM2CHRM4CHRM5
SCHEMBL2625322 0.68 TDP2 (0.40) KCNH2ADORA3L3MBTL1KDM4EALDH1A1
SCHEMBL2625325 0.68 HSF1 (0.35) KCNH2SIGMAR1ADORA3L3MBTL1KDM4E
SCHEMBL2625330 0.64 TLR9 (0.40) KCNH2ADORA3L3MBTL1KDM4EALDH1A1
SCHEMBL2625323 0.62 HTR1A (0.39) KCNH2ADORA3KDM4EALDH1A1NPC1
SCHEMBL13910152 0.60 NPC1 (0.53) ADORA3L3MBTL1KDM4EALDH1A1NPC1
SCHEMBL13910155 0.60 NPC1 (0.53) ADORA3L3MBTL1KDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165313-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2012-06-28 US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165313-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE MTOR, TYMS, DTYMK KCNH2 4005/4885SIGMAR1 2907/4885CHRM2 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.